The Paradigm Shift from Traditional Scientific Platforms to Integrated Communications Plans

In the rapidly evolving biopharma landscape, the approach to scientific communications is undergoing a significant transformation. The shift from traditional scientific platforms to integrated communications plans (ICPs) is becoming increasingly crucial for ensuring cohesive and impactful messaging. This article delves into the components, implementation, and benefits of an ICP tailored for the biopharma industry, addressing the challenges of fragmented messaging and the need for a unified communication strategy...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Health Literacy Month

Celebrating Health Literacy Month 2024:

October is Health Literacy Month, a reminder of the...
To preprint or not to preprint: A debate at the ISMPP

To Preprint or Not to Preprint: Debate at the 17th Annual ISMPP Meeting

The Covid-19 pandemic has brought with it a deluge of preprints. While timely sharing of...
Digital therapeutics and medical communications

Digital Therapeutics and Medical Communications: Are We Ready?

Digital Therapeutics are very new and complex, and their use will involve changing standard therapeutic...
EU MedTech Summit 2020

EU MedTech Summit 2020: Highlights and Top 3 Takeaways

How is the MedTech industry gearing up for the EU-MDR? Here are some key takeaways...
EU MDR Whitepaper

EU MDR: Increasing Expectations for Clinical Evidence

While the global medical devices industry is closely watching how the European Union (EU) Medical...
Medical writing and communication during the COVID-19 crisis

Medical Writing and Medical Communication during COVID-19 Crisis: AMWA Virtual Event

How medical writers and science communicators are called to respond to the COVID-19 infodemic...

Learn more ABOUT our company.